PT - JOURNAL ARTICLE AU - Jorge Angel Almeida Villegas AU - Mariana Islas Rodriguez AU - Iris Mellolzy Estrada AU - Miriam Deyanira Rodriguez AU - María Carolina Erazo Muñoz AU - Silvia Patricia Rodriguez TI - Antibiotic resistance in clinical isolates of <em>Escherichia coli</em> non-producer of Extended Spectrum Betalactamases (ESBL), obtained from urine cultures in patients with urinary tract infection AID - 10.1101/2020.08.15.20173146 DP - 2020 Jan 01 TA - medRxiv PG - 2020.08.15.20173146 4099 - http://medrxiv.org/content/early/2020/08/19/2020.08.15.20173146.short 4100 - http://medrxiv.org/content/early/2020/08/19/2020.08.15.20173146.full AB - Objective To identify strains of Escherichia coli that do not produce Extended Spectrum Betalactamases (ESBL) in urine cultures and to evaluate the patterns of resistance to certain antibiotics used in clinical practice as treatments of choice in the Toluca Valley of Mexico.Method 155 urine samples were obtained from people in the Toluca Valley, Mexico under necessary hygiene conditions. 100ml used to identify the pathogen and its resistance patterns were collected from each sample, using an automated Walkaway method.Result 19 strains of non-ESBL-producing Escherichia coli were obtained, of which 68.42% showed resistance to ampicillin and tetracycline, 47.36% resistance to trimethoprim with sulfamethoxazole, 26.31% for levofloxacin, ciprofloxacin, ceftriaxone, and resistance of 21 % with ampicillin and sulbactam. 100% sensitivity for amikacin, tigecycline and carbapenems.Conclusion Antibiotic resistance represents a major health problem, as the present study shows, ampicillin is a drug of choice for urinary tract infection produced by Eschericha coli, but in the Toluca Valley the resistance to this antibiotic is 68.42% In non-ESBL producing strains, high resistance patterns are also shown for quinolones, tetracycline and trimethoprim with sulfamethoxazole.Competing Interest StatementThe authors have declared no competing interest.Funding Statement The authors declare that they have no conflict of interest. No funding was received to carry out this work. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Microtec Laboratories Ethics Committee has indicated that the research project does not need approval.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesReaders will be able to access the data here present, citing and giving credit to the authors of this research work.